Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
lunsekimig (SAR443765) / Sanofi
NCT06454240: A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps	Recruiting	2	80	Europe, US, RoW	lunsekimig, SAR443765, placebo	Sanofi	Chronic Rhinosinusitis With Nasal Polyps	01/27	04/27
AIRPHRODITE, NCT06609239: Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Moderatetosevere Asthma.	Recruiting	2	467	US, RoW	Lunsekimig, SAR443765	Sanofi	Asthma	01/31	01/31
AIRLYMPUS, NCT06676319: Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma	Recruiting	2	1000	Europe, Canada, US, RoW	Lunsekimig, SAR443765, Short-Acting Beta Agonists (SABA), Placebo, Fluticasone/salmeterol, Budesonide/formoterol	Sanofi	Asthma	10/27	11/27
AIRCULES, NCT06102005: Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma	Recruiting	2	630	Europe, Canada, Japan, US, RoW	Lunsekimig, Placebo	Sanofi	Asthma	06/26	06/26
NCT05366764: First-in-human Study of SAR443765 in Healthy Participants and in Asthmatic Participants	Completed	1	36	Europe	SAR443765, Placebo, Salbutamol or levosalbutamol	Sanofi	Asthma	02/23	02/23